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Aim To compare cognitive fusion targeted and systemat-
ic prostate biopsy in patients with repeated negative sys-
tematic biopsy but persistent clinical suspicion for prostate 
cancer.
Methods The study enrolled 63 patients with at least one 
previously negative systematic biopsy who underwent 
targeted prostate biopsy using multiparametric magnet-
ic resonance imaging (mpMRI) and transrectal ultrasound 
(TRUS) in addition to standardized systematic biopsy from 
July 2016 to May 2018. Multiparametric MRI was performed 
with 3 Tesla device by uro-radiologists experienced in pros-
tate cancer. Lesions with Prostate Imaging Reporting and 
Data System 3, 4, and 5 were considered suspicious. Tar-
geted biopsies were performed with cognitive fusion of 
TRUS and mpMRI.
Results Prostate cancer detection, using either targeted 
or systematic biopsy, was 60.32%. Targeted biopsies were 
positive in 52.38% and systematic biopsies in 47.62% of pa-
tients. The median highest percentage of cancer involve-
ment per biopsy core was significantly higher in targeted 
cylinders. The biopsies obtained by using the two tech-
niques did not significantly differ in Gleason score.
Conclusion Cognitive targeted prostate biopsy based on 
mpMRI presents a valuable addition to systematic biopsy 
in patients with repeated negative systematic biopsies but 
persistent clinical suspicion of prostate cancer.
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Prostate cancer is the second most common malignant 
neoplasm and the fifth leading cause of death in the male 
population, with the expected increase in incidence and 
mortality due to global population aging (1). In Croatia, it 
is the second most common cancer in terms of incidence 
and mortality (2). Patients with clinical suspicion of pros-
tate cancer (prostate specific antigen [PSA]>4.0 ng/mL, ab-
normal digital rectal exam) undergo systematic transrec-
tal ultrasonography (TRUS)-guided biopsy, during which 
10 to 12 cores of prostate tissue are obtained for patho-
histological evaluation (3). Such non-targeted, systematic 
biopsy may overdiagnose insignificant cancer and under-
diagnose clinically significant cancer, particularly cancers 
located in the apical and anterior prostate zones (4-6). 
The overdiagnosis of clinically insignificant prostate can-
cer leads to overtreatment, higher psychological burden, 
and treatment complications, which all results in increased 
health care system expenses.
In recent years, multiparametric magnetic resonance im-
aging (mpMRI) has shown promise as a diagnostic tool 
for prostate cancer. The combination of anatomic, T1, T2, 
functional, diffusion weighted, and dynamic contrast en-
hance imaging provides good sensitivity for the detec-
tion and localization of tumors with the Gleason score ≥7 
(7,8). Targeted biopsies based on mpMRI are more likely 
to help diagnose clinically significant prostate cancer and 
reduce the number of diagnoses of clinically insignificant 
cancers compared with systematic biopsies, thus reducing 
the number of overtreated patients and treatment costs 
(9-11). In PROMIS study, when compared with TRUS biopsy, 
mpMRI-based targeted biopsy had a higher sensitivity and 
negative predictive value for diagnosing clinically signifi-
cant prostate cancer (9).
Patients with a negative systematic biopsy but with pres-
ent clinical suspicion for prostate cancer due to elevated 
PSA levels present an unresolved diagnostic challenge. The 
repeat biopsy after a negative first systematic biopsy using 
TRUS was positive for prostate cancer in about 30% of pa-
tients, a substantially lower rate compared with that of sat-
uration biopsy (12,13). In another study, the first systematic 
biopsy controlled by TRUS was positive in 20% of patients, 
while the fourth biopsy was positive in only 4% of patients 
(14). Due to the poor results of repeated systematic biop-
sies, these patients are recommended to undergo a tar-
geted biopsy with mpMRI (15).
The aim of this study is to compare cognitive fusion 
targeted and systematic prostate biopsy in patients 
with repeated negative systematic biopsy but persistent 
clinical suspicion for prostate cancer.
PATIenTS And MeTHodS
Patients
We prospectively enrolled 63 male patients treated at the 
Department of Urology, University Hospital Center Zagreb 
from July 2016 to May 2018. The patients underwent cog-
nitive targeted prostate biopsy by using mpMRI and TRUS 
after at least one previously negative systematic biopsy. 
Power analyses based on the data from previous studies 
yielded 80% power and alpha value of 0.05, indicating that 
39 patients were needed to show the difference between 
targeted and systematic biopsy. Inclusion criteria were still 
present clinical suspicion of prostate cancer due to con-
stantly elevated or rising PSA (>4 ng/mL) and PI-RADS 3-5 
lesion identified using mpMRI. The study was approved by 
the Ethics Committee of Zagreb University Hospital Center 
(02/21 AG).
MRI specification and technique
All MRI examinations were performed with a 3T Siemens 
Prisma scanner (Siemens Medical Solutions, Erlangen, Ger-
many) by using a phased array coil. T2-weighted images 
were taken in the sagittal, coronal, and transversal planes 
with the 200 mm ×200 mm field-of-view, 3-mm slice thick-
ness, repetition time of 6000-6620 ms, and echo time 
of 91-101 ms. Diffusion-weighted sequences were per-
formed with the b values of 0 s/mm2, 500 s/mm2, 1500 s/
mm2, and 2000 s/mm2. Dynamic sequences consisted of 
T1-weighted fat saturated images with 320 mm ×206 mm 
FOV, 3-mm slice thickness, TR 4 ms, TE 1 ms, before and 50 
times after the administration of 0.2 mL/kg gadopentetate 
dimeglumine (Dotarem, Guerbet S.A., France) at a concen-
tration of 0.5 mmol/mL. All mpMRI findings were interpret-
ed by uro-radiologists experienced in prostate cancer. Ac-
cording to the version 2 of Prostate Imaging Reporting and 
Data system (PI-RADS), lesions with PI-RADS 3, 4, and 5 on 
mpMRI were considered suspicious (16).
Biopsy technique and pathohistological evaluation
All targeted and systematic biopsies were performed by the 
same urologist with an ultrasound station (Flex Focus 500, 
BK Medical, Denmark) and ultrasound probe (8818, BK Med-
ical, Denmark) with 18G biopsy needles. Biopsies were per-
formed in the axial plane by using the end-fire technique. A 
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6-core targeted biopsy was focused on the suspicious lesion 
as shown by mpMRI. The targeted biopsy was followed by 
12-core standard systematic biopsy. If more than one sus-
picious lesion was identified on mpMRI, 3 cores from each 
of the two most suspicious lesions were sampled. There is 
no current consensus on the number of targeted cylinders. 
According to Mottet et al (3), at least 2 cores should be tak-
en from the suspicious lesions. However, in many European 
urology centers, 4-6 cores are usually taken.
Before the cores were taken, patients received periprostatic 
block with 2% lidocaine (17). All patients received oral cipro-
floxacin prophylaxis (18). The samples were examined by pa-
thologists experienced in urological pathology to determine 
the Gleason score and percentage of core cancer involve-
ment (19). The samples of 17 patients who underwent radi-
cal prostatectomy (RP) were pathohistologically evaluated.
Statistical analysis
Descriptive statistics was used to describe patients’ age, 
PSA, the number of previous biopsies, dimensions of the 
largest suspicious lesion on mpMRI, PI-RADS score, loca-
tion of suspicious lesion on mpMRI, number of positive 
cores, the Gleason score in targeted and systematic biop-
sies, percentage of core cancer involvement of targeted 
and systematic cores, positivity of targeted and systematic 
biopsies, and clinical significance of prostate cancer.
The Wilcoxon signed rank test was used to compare the 
greatest percentage of cancer involvement and the Glea-
son scores between targeted and systematic cores. The 
McNemar test was used to compare the Gleason scores of 
targeted and systematic biopsies with the Gleason scores 
determined at pathohistological evaluation after RP. The 
level of statistical significance was set at less than 0.05. The 
analysis was conducted with SPSS, v. 25.0 software (IBM, 
Amonk, NY, USA).
ReSuLTS
The median age was 67 years (range, 57-84). In all patients, 
mpMRI was performed after at least one negative system-
atic biopsy using TRUS. The median number of biopsies 
that preceded mpMRI was 2 (range, 1-8). The median PSA 
value was 10.70 (range, 4.86-64.00) ng/mL. Digital rectal ex-
amination was unsuspicious for prostate cancer in all pa-
tients. The median size of the largest suspicious lesion on 
mpMRI was 1.30 cm (range, 0.4-3.00).
Overall prostate cancer detection, using either targeted or 
systematic biopsy, was 60.32% (38/63 patients). System-
atic biopsies were positive in 30/63 patients (47.62%) and 
targeted biopsies in 33/63 patients (52.38%). The median 
number of positive cylinders in targeted biopsies was 4/6 
(range, 0-6) and the median number of positive cylinders 
in systematic biopsies was 2/12 (range, 0-8). The median 
highest percentage of cancer involvement per biopsy core 
was 70% (range, 5%-90%) for targeted and 20% (range, 
5%-90%) for systematic biopsy. According to the criteria by 
Klotz et al (GS≤6, clinical T1-2, PSA<10), the tumor found 
in systematic cores was low-risk in 8 patients (26.67%) and 
the tumor found in targeted cylinders was low risk in 6 
patients (18.18%) (20). Prostate cancer was diagnosed in 
8.33%, 45.71%, and 100% of PI-RADS 3, 4, and 5 lesions, re-
spectively.
Thirty-six of 51 patients with PI-RADS 4 and 5 (70.59%) had 
prostate cancer in at least one cylinder, whether systematic 
or targeted. In 8 patients with PI-RADS 4 and 5 (15.69%), only 
targeted biopsy was positive, whereas in 4 patients (7.84%) 
only systematic biopsy was positive. On average, in patients 
with PI-RADS 4 and 5, there were 3 positive targeted (range, 
0-6) and 2 positive systematic cylinders (range, 0-8).
Two of 12 patients with PI-RADS 3 lesion on mpMRI had 
positive biopsies. Targeted biopsy was positive in 1 patient 
and systematic biopsy in 2 patients (Table 1). The targeted 
biopsy had Gleason score 7, while both systematic biop-
sies had Gleason score 6.
Comparison between targeted and systematic biopsies
Targeted cores had significantly higher percentag-
es of cancer core involvement than systematic cores 
(P = 0.003). Patients with positive systematic and target-
TABLe 1. Biopsy data according to Prostate Imaging Reporting and data System (PI-RAdS) score
Positive finding Cancer core involvement
PI-RAdS score Patients, n (%) systematic biopsy, n (%) targeted biopsy, n (%) systematic biopsy (%) targeted biopsy (%)
3 12/63 (19.05)  2/12 (16.67)  1/12 (8.33) 10 50
4 35/63 (55.56) 18/35 (51.43) 16/35 (45.71) 20 55
5 16/63 (25.40) 10/16 (62.50) 16/16 (100) 20 60
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ed biopsy did not significantly differ in the Gleason score 
(P = 0.49). Targeted and systematic biopsies had an equal 
Gleason score in 19 cases. Systematic biopsies had a low-
er score in 5 cases and a higher score in 3 cases. In 17 
patients in whom radical prostatectomy (RP) specimen 
was used as a control, systematic and targeted biopsy 
both matched the Gleason score of RP in 6 cases. Over-
all, targeted biopsy in more cases matched the Gleason 
score of RP specimen, but the difference was not signifi-
cant (P = 0.219).
The majority of suspicious lesions were found in the transi-
tional, anterior, and apical zones, and only 14.3% of lesions 
found using mpMRI were located in the peripheral zone 
(Table 2).
dISCuSSIon
In this study, the mpMRI performed before the repeated 
prostate biopsy helped in diagnosing prostate cancer in 
patients with a persistent clinical suspicion of prostate can-
cer due to elevated PSA values and present suspicious le-
sion on mpMRI but negative systematic biopsy.
There are three techniques of targeted prostate biopsy us-
ing the mpMRI: 1) cognitive MR imaging-targeted biopsy, 
2) transrectal US-MR imaging fusion targeted biopsy 3) 
in-gantry MR imaging-targeted biopsy (21). Studies show 
that the three techniques do not significantly differ in the 
detection of clinically significant prostate cancer (10,22). In 
our study, we used cognitive MRI-targeted biopsy because 
it is a simple and quick technique that requires no new 
hardware, meaning there are no additional expenses for 
the hospital. However, the operator must be aware of the 
systemic biases caused by the fact that axial TRUS images 
are not obtained along the same plane as the MR images, 
although they look similar (23). This bias can lead to inac-
curate targeting, particularly of the anterior and posterior 
lesions, and has to be taken into account when perform-
ing targeted biopsy with TRUS (24). The accuracy of this 
method highly depends on the operator’s under-
standing of the prostate MRI and the ability to correlate 
MRI targets to real-time TRUS images (15).
Despite the study limitations, primarily a highly selected 
subgroup of patients, certain conclusions can be made. We 
showed that neither systematic 12 core biopsy obtained 
using TRUS nor targeted biopsy using the cognitive fusion 
of mpMRI and TRUS technique can detect all cancers. The 
targeted biopsy was still somewhat superior to systemat-
ic biopsy, with a detection rate of 52.38% compared with 
47.62%. However, the unexpectedly high positivity of sys-
tematic biopsy in our study could be explained by the fact 
that the operator, deliberately or not, directed the systemic 
biopsy toward the location of the suspicious lesion found 
on mpMRI. In 8 patients (15.69%), only targeted cores were 
positive and these findings are similar to the findings by 
Boesen et al (25).
A strength of our study is that we used pathohistological 
evaluation after RP as the control in 17 patients. Targeted 
biopsy undergraded prostate cancer in 6 cases (35.29%) 
and systematic biopsy undergraded it in 11 cases (64.71%), 
but the difference was not significant.
In our series, the prostate cancer detection rate using tar-
geted and systematic approach based on mpMRI findings 
(60.31%) was higher than the detection rate found by Bo-
esen et al (47%) and lower than that found by Delong-
champs et al (67%) (25,26).
A low detection rate in patients with PIRADS 3, but high in 
those with PIRADS 5 lesions was consistent with the find-
ings by Pokorny et al, indicating that patients with PIRADS 
3 had a small benefit from a repeated biopsy (27).
If we had performed only targeted biopsy, we would have 
misdiagnosed 5 patients (13.16%), one of them with the 
Gleason score 8 on pathohistological evaluation after radi-
cal prostatectomy. This finding suggests that systematic bi-
opsy is a necessary addition to targeted biopsy if we want 
to misdiagnose as few patients as possible (15,27-29).
TABLe 2. Positivity of systematic and targeted biopsy according to lesion location on multiparametric magnetic resonance imaging 
(mpMRI)
Lesion location on mpMRI number (%) Positive systematic biopsy, n (%) Positive targeted biopsy, n (%) overall positivity, n (%)
Central/transitional 42/63 (66.67) 17/42 (40.48) 20/42 (47.62) 22/42 (52.38)
Peripheral  9/63 (14.29)  7/9 (77.78)  5/9 (55.56)  8/9 (88.89)
Apical  9/63 (14.29)  5/9 (55.56)  6/9 (66.67)  6/9 (66.67)
Anterior  3/63 (4.76)  1/3 (33.33)  2/3 (66.67)  2/3 (66.67)
53Kuliš et al: Targeted prostate biopsy using a cognitive fusion of multiparametric MRI and transrectal ultrasound
www.cmj.hr
The majority of suspicious lesions were located in the tran-
sitional, anterior, and apical zones, and only 14.3% of le-
sions found using mpMRI was were located in the periph-
eral zone This percentage was lower than in the study by 
Schouten et al (30%), possibly because they included more 
patients (30). The patients with lesions in the transitional, 
anterior, and apical zones had on average three previous-
ly negative biopsies because systematic biopsy is used for 
sampling primarily the peripheral zone. The use of end fire 
probe enabled the operator to reach the central and more 
apical portions of the prostate, otherwise inaccessible to 
sampling when using side fire probe for systematic 12-
core biopsy.
We also showed that targeted biopsy matched the Glea-
son score of RP specimens more accurately than systemic 
biopsy, but without significant difference.
Our study demonstrated that the targeted approach 
based on mpMRI presented a valuable addition to system-
atic biopsy in diagnosing patients with repeated negative 
systematic biopsies but with constantly elevated or rising 
PSA. We expect that more experience in performing tar-
geted mpMRI biopsies, as well as the development of mp-
MRI and targeted prostate biopsy techniques, will help us 
to perform only targeted repeat biopsies and omit system-
atic biopsy altogether.
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